The Influence of the Ketogenic Diet on the Immune Tolerant Microenvironment in Glioblastoma.
Document Type
Article
Publication Date
11-11-2022
Publication Title
Cancers (Basel)
Abstract
Glioblastoma (GBM) represents an aggressive and immune-resistant cancer. Preclinical investigations have identified anti-tumor activity of a ketogenic diet (KD) potentially being used to target GBM's glycolytic phenotype. Since immune cells in the microenvironment have a similar reliance upon nutrients to perform their individual functions, we sought to determine if KD influenced the immune landscape of GBM. Consistent with previous publications, KD improved survival in GBM in an immune-competent murine model. Immunophenotyping of tumors identified KD-influenced macrophage polarization, with a paradoxical 50% increase in immune-suppressive M2-like-macrophages and a decrease in pro-inflammatory M1-like-macrophages. We recapitulated KD in vitro using a modified cell culture based on metabolomic profiling of serum in KD-fed mice, mechanistically linking the observed changes in macrophage polarization to PPARγ-activation. We hypothesized that parallel increases in M2-macrophage polarization tempered the therapeutic benefit of KD in GBM. To test this, we performed investigations combining KD with the CSF-1R inhibitor (BLZ945), which influences macrophage polarization. The combination demonstrated a striking improvement in survival and correlative studies confirmed BLZ945 normalized KD-induced changes in macrophage polarization. Overall, KD demonstrates antitumor activity in GBM; however, its efficacy is attenuated by promoting an immunosuppressive phenotype in macrophages. Combinatorial strategies designed to modulate macrophage polarization represent a rational approach to improve the anti-tumor activity of KD in GBM.
Volume
14
Issue
22
First Page
5550
Recommended Citation
Kesarwani P, Kant S, Zhao Y, Miller CR, Chinnaiyan P. The influence of the ketogenic diet on the immune tolerant microenvironment in glioblastoma. Cancers (Basel). 2022 Nov 11;14(22):5550. doi: 10.3390/cancers14225550. PMID: 36428642.
DOI
10.3390/cancers14225550
ISSN
2072-6694
PubMed ID
36428642